TABLE 1.
Clinicopathological characteristics of our patients.
| Case no | Sex/age at diagnosis | Diagnosis | Localisation | Antibodies |
|---|---|---|---|---|
| 1 | M/78 | DI-SCLE (nivolumab 6th dose) | Chest, arms, back | ANA, SSA |
| 2 | F/71 | DI-SCLE (pembrolizumab 1st dose) | Arms | ANA |
| 3 | F/72 | I-SCLE | Neck, V-line, arms, back | ANA, SSA |
| 4 | F/77 | I-SCLE | Face, chest, arms, shoulders, back, buttocks, legs | ANA, SSA, SSB, RF |
| 5 | M/43 | DLE | Nose | None |
| 6 | M/37 | DLE | Face | None |
| 7 | F/31 | DLE | Face, back | None |
| 8 | F/45 | DLE | Face, back, scalp | None |
| 9 | F/72 | TEN-like lupus | Widespread | ANA, dsDNA |
| 10 |
M, male; F, female; SCLE, subacute cutaneous lupus erythematosus; DI-SCLE, PD-1 inhibitor-induced SCLE; I-SCLE, idiopathic SCLE; DLE, discoid lupus erythematosus; TEN, toxic epidermal necrolysis; ANA, anti-nuclear antibody; SSA, anti-Sjögren’s-syndrome-related antigen A; SSB, anti-Sjögren’s-syndrome-related antigen B; RF, rheuma factor; dsDNA, double stranded deoxyribonucleic acid.